AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00536263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b
Description: 1.5 mcg/kg S.C. QW for 48 weeks
Study NCT03061682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scharioth macula lens A45sml/A45smy
Description: Implantation of an add on intraocular lens to low vision patients
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride placebo
Description: finasteride placebo, by mouth once daily
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride placebo
Description: dutasteride placebo, by mouth once daily
Study NCT01231607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride placebo
Description: dutasteride placebo, by mouth once daily
Study NCT01203787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Standard Dosing Regimen
Description: Sorafenib 400 mg twice daily until wk 24 or end of treatment
Study NCT01203787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Ramp-Up Regimen
Description: 200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
Study NCT03129633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: One-on-one contact with a promotor(a) over the 6 month intervention.
Study NCT05594433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: Injection sub cutaneous of Lenograstim during 4 days, once per day
Study NCT04527276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral care with 0,12% Chlorhexidine
Description: 0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
Study NCT03620435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
Study NCT00702910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: comparator
Study NCT00702910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator
Study NCT00702910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: investigational drug or placebo
Study NCT00702910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW642444
Description: investigational drug or placebo
Study NCT00702910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Stearate
Description: Magnesium Stearate
Study NCT00702910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Stearate
Description: Magnesium Stearate
Study NCT01294982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOBO-001
Description: AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
Study NCT01294982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOBO-001
Description: AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
Study NCT01294982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Capsules twice daily
Study NCT00744848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 100 mg Bupivacaine HCl
Study NCT00744848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SKY0402
Description: Single administration 300 mg SKY0402 in a 40-mL injection volume
Study NCT00003735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: given by mouth
Study NCT02890732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appet HEART
Description: smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
Study NCT02847845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red ginseng powder capsule
Description: usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
Study NCT02847845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
Study NCT05567393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching SC injection
Study NCT05567393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 SC injection
Study NCT03551613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: honey supplementation
Description: honey supplementation
Study NCT03551613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: honey supplementation
Description: honey supplementation
Study NCT02406521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT02406521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT02406521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Study NCT04244071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Paws Blanket 81003 and FOC device 87500
Description: This study is a randomized, pretest - posttest controlled experimental design.
Study NCT04244071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine hospital care
Description: routine hospital care
Study NCT02415088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective shoulder block
Description: selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
Study NCT01264289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride Tablets 5 mg
Study NCT04244071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine hospital care
Description: routine hospital care
Study NCT00506467 — intervention group
Intervention type: PROCEDURE
Intervention: Vibration Response Imaging
Description: Lung function test performed using the VRI system immediately before or after the standard lung function test.
Study NCT03552107 — intervention group
Intervention type: DRUG
Intervention: Lorcaserin
Description: Treatment initiation with Lorcaserin
Study NCT02163577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burosumab
Description: solution for SC injection
Study NCT03951285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NR in BMI-discordant twins
Description: Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
Study NCT03951285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NR in BMI-concordant twins
Description: Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
Study NCT03951285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NR in BMI-concordant twins
Description: Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
Study NCT02849327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT03621059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: habit reversal training (HRT)
Description: The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)
Study NCT05033574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical study of hormone levels
Description: Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr
Study NCT00639288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified CPT-C
Description: modified CPT-C
Study NCT06100757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micra Transcatheter Pacing System (TPS°
Description: Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
Study NCT06100757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR
Description: Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
Study NCT01273038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morfeus
Description: The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
Study NCT01273038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: The CE marked ostomy bag filter will be tested for a period of 14 days
Study NCT04125173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure = 15mmHg
Description: Randomized pneumoperitoneum 1
Study NCT04125173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure = 12mm Hg
Description: Randomized pneumoperitoneum 2
Study NCT01264289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride Tablets 5 mg
Study NCT01863485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 Tablet
Description: CM082 tablets taken orally once a day on 28-day cycles
Study NCT04125173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure = 10mmHg
Description: Randomized pneumoperitoneum 3
Study NCT05420415 — intervention group
Intervention type: OTHER
Intervention: CSTME
Description: Tumor microenvironment collagen signature
Study NCT01097148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium, TBW
Description: Dose atracurium 0.5 mg/kg based on total body weight
Study NCT03683056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I Can Problem Solve (ICPS) Program
Description: The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
Study NCT00106288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT00106288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: IV
Study NCT03923439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-b diffusion sequence MRI
Description: Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
Study NCT01274117 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transposition of the basilic vein and anastomosis with the brachial vein
Description: One-stage vs two-stage transposition of the basilic vein
Study NCT01274117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transposition of the basilic vein and anastomosis with the brachial vein
Description: One-stage vs two-stage transposition of the basilic vein
Study NCT01976299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVERT
Study NCT01343745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/formoterol
Description: pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
Study NCT01343745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/formoterol
Description: pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
Study NCT04655703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DJO X4 brace with Motion Intelligence Platform
Description: The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
Study NCT01343745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pressurised metered dose inhaler
Study NCT03410069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IKORUS UP system
Description: Continuous assessment of the urethral microcirculation
Study NCT02250872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin
Description: Gemigliptin 100mg in 2 divided doses plus cisplatin
Study NCT02250872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg in 2 divided doses plus cisplatin
Study NCT02250872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: All patients will receive intravenous cisplatin
Study NCT02250872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: All patients will receive intravenous cisplatin
Study NCT01716364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-LeY- scFv-CD28-ζ vector,.
Study NCT02837718 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bupivakain % 0,5
Description: Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
Study NCT02817178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional biological samples
Description: blood and tumor tissue samples
Study NCT02194556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential and maintenance icotinib
Description: Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
Study NCT02194556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance icotinib
Description: Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
Study NCT05868980 — intervention group
Intervention type: OTHER
Intervention: vital signs by postpartum position
Description: Evaluation of vital signs and NIRS values in 4 different positions after birth
Study NCT04298489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Personalized drug sensitivity test
Description: The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software.
Study NCT00978224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: 3 Viusid bags (Orally administered) per day, for 60 weeks
Study NCT00978224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 Placebo bags (Orally administered) per day, for 60 weeks.
Study NCT00438919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: CYPHER SELECT™ Sirolimus-eluting Coronary Stent
Study NCT00291499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin 4&6 sulfate (Condrosulf)
Description: 800 mg/day for 6 months
Study NCT00291499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 mg placebo/day for 6 months
Study NCT04516577 — intervention group
Intervention type: OTHER
Intervention: Assesssing the severity of pulmonary alveolar proteinosis
Description: Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
Study NCT01040338 — intervention group
Intervention type: DRUG
Intervention: Nicotine
Description: Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
Study NCT01194869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
Study NCT01194869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² given IV
Study NCT01194869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² given IV
Study NCT02474914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide will be given after PD
Study NCT02474914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Octreotide will NOT be given after PD
Study NCT04199793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lavare On
Description: For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room.
Study NCT04199793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lavare Off
Description: For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room.
Study NCT03058822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: BMS-931699 single subcutaneous dose on Day 1
Study NCT01078987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Description: A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
Study NCT02333006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
Study NCT01256203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solar Protection Formula SPF® 60
Description: Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
Study NCT01256203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiological testing
Description: Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.